Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · non response in schizophrenia
It is very uncertain whether antipsychotic dose increase changes leaving the study early: tolerability ‐ leaving early due to adverse… compared with antipsychotic dose continuation (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes leaving the study early: Any reason ‐ all doses risperidone depot ‐… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · patients with people with severe mental illnesses
SHORT showed no clear difference in leaving the study early (long term) Participants leaving the study… compared with LONG HOSPITAL STAY (low certainty).
1 finding from 1 review
Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia
It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia
It is very uncertain whether BENZODIAZEPINES AS SOLE TREATMENT changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO (very low certainty).
1 finding from 1 review
Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia
It is very uncertain whether BENZODIAZEPINES changes leaving the study early due to any reason (overall acceptability of… compared with ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Intervention not reported
Non‐compliance leaving the study early (endpoints fall between 1 and 6 months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
Adverse effects*: leaving the study early ‐ did not leave · patients with schizophrenia
VIDEO GAMES (COMMERCIAL NON‐EXERGAMES) (plus standard care) showed no clear difference in adverse effects*: leaving the study early ‐ did not leave ‐ by end… compared with COGNITIVE REMEDIATION (plus standard care) (low certainty).
1 finding from 1 review
Leaving the study early (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. standard higher dose (>… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Acceptability · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Acceptability · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether benzodiazepines changes acceptability of the treatment (measured by participants leaving the… compared with placebo (very low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · non response in schizophrenia
1 finding from 1 review
Leaving the study early Leaving the study early: participants lost to · patients with schizophrenia
1 finding from 1 review
Leaving the study early ‐ due to adverse effects (short term) · non response in schizophrenia
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · patients with schizophrenia
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · patients with schizophrenia
It is very uncertain whether BENZODIAZEPINES changes leaving the study early due to adverse effects (overall tolerability… compared with ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Satisfaction and acceptability of treatment (medium term) ‐ leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether ECT plus standard care changes satisfaction and acceptability of treatment (medium term) ‐ leaving… compared with standard care (very low certainty).
1 finding from 1 review
Acceptability (of intervention): Leaving the studies early – any reason Loss to · patients with treatment compliance for people with serious mental illness
1 finding from 1 review
Leaving the study early: Any reasons ‐ when compared with ultra low dose (<2 mg/day) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with ultra low… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Satisfaction with treatment: 1. Leaving the study early ‐ long term · people in the prodromal stage of psychosis
It is very uncertain whether group C other: cognitive training changes satisfaction with treatment: leaving the study early Endpoint data… compared with active control (tablet games) (very low certainty).
1 finding from 1 review